BAX:NYE-Baxter International Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 32.63

Change

-1.20 (-3.55)%

Market Cap

USD 17.26B

Volume

5.37M

Analyst Target

USD 96.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois. Address: One Baxter Parkway, Deerfield, IL, United States, 60015

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

-0.05 (-0.02%)

USD 66.85B
ALC Alcon AG

+0.60 (+0.69%)

USD 43.35B
RMD ResMed Inc

-11.77 (-4.76%)

USD 35.86B
AVTR Avantor Inc

-0.21 (-0.96%)

USD 14.69B
ATR AptarGroup Inc

-0.20 (-0.11%)

USD 11.68B
TFX Teleflex Incorporated

-1.60 (-0.82%)

USD 9.08B
BLCO Bausch + Lomb Corp

+0.22 (+1.13%)

USD 6.88B
STVN Stevanato Group SpA

-0.19 (-0.92%)

USD 5.19B
WRBY Warby Parker Inc

-0.11 (-0.52%)

USD 2.03B
INFU InfuSystems Holdings Inc

-0.58 (-6.10%)

USD 0.17B

ETFs Containing BAX

PBI Pitney Bowes Inc 0.00 % 0.79 %

-0.17 (-2.22%)

USD 1.34B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.60% 21% F 12% F
Dividend Return 2.25% 80% B- 41% F
Total Return -13.35% 32% F 12% F
Trailing 12 Months  
Capital Gain -7.59% 32% F 13% F
Dividend Return 3.29% 80% B- 44% F
Total Return -4.30% 32% F 14% F
Trailing 5 Years  
Capital Gain -59.93% 6% D- 7% C-
Dividend Return 6.68% 57% F 17% F
Total Return -53.25% 6% D- 7% C-
Average Annual (5 Year Horizon)  
Capital Gain -18.04% 5% F 3% F
Dividend Return -16.44% 5% F 3% F
Total Return 1.60% 78% C+ 39% F
Risk Return Profile  
Volatility (Standard Deviation) 17.72% 84% B 61% D-
Risk Adjusted Return -92.78% 5% F 1% F
Market Capitalization 17.26B 79% B- 90% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector